Collegium Pharmaceutical, Inc. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
Collegium Pharmaceutical, Inc. (COLL) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $646.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-06-30 was $646.00K, a 50.93% increase year-over-year.
- Collegium Pharmaceutical, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-03-31 was $15.43M, a 45.69% increase year-over-year.
- Collegium Pharmaceutical, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-09-30 was $964.00K, a 578.87% increase year-over-year.
- Collegium Pharmaceutical, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-06-30 was $428.00K, a 92.71% decline year-over-year.
- Collegium Pharmaceutical, Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2025 was $12.85M, a 32.99% decline from fiscal 2024.
- Collegium Pharmaceutical, Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2024 was $19.17M, a 129.28% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2023 was $8.36M.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $646.00K 10-Q · filed 2026-08-06 | $16.08M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $15.43M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $12.85M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $964.00K 10-Q · filed 2025-11-06 | $1.39M derived: sum of 2 quarters · filed 2026-08-06 | $11.98M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $428.00K 10-Q · filed 2026-08-06 | $11.02M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $10.59M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $19.17M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $142.00K 10-Q · filed 2025-11-06 | $6.02M derived: sum of 2 quarters · filed 2025-11-06 | $18.89M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $5.88M 10-Q · filed 2025-11-06 | $18.75M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $12.87M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $8.36M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |